A large randomized clinical trial is necessary to establish the role of camrelizumab in hepatocellular carcinoma

Ann Transl Med. 2020 Oct;8(19):1253. doi: 10.21037/atm-2020-71.

Authors

Nishal Ravindran¹, Paul J Thuluvath^{1

2}

Affiliations

¹ Institute of Digestive Health and Liver Diseases, Mercy medical Center, Baltimore, MD, USA.
² Department of Medicine, University of Maryland School of Medicine, Baltimore, MD, USA.

No abstract available

Publication types

Editorial
Comment